FMED vs IHI

Key Takeaways

• FMED is an actively managed thematic ETF targeting disruptive innovations across healthcare subsectors like biotech and gene therapy, while IHI is a passive index-tracking fund focused exclusively on U.S. medical device manufacturers.
• FMED holds approximately 67-74 securities with top 10 comprising around 30-38% of assets, offering broader diversification; IHI has about 47-52 holdings where top 10 account for over 75%, indicating higher concentration risk.
• Both ETFs are 100% allocated to healthcare, but FMED includes biotech (43%), pharmaceuticals, and services, whereas IHI targets medical equipment like imaging and prosthetics.
• IHI features a lower expense ratio of 0.38% compared to FMED's 0.50%, providing cost efficiency for long-term holders.
• IHI demonstrates superior liquidity with billions in assets under management (AUM, total assets in the fund) versus FMED's smaller scale, appealing to institutional investors.
• FMED's active strategy allows flexibility for emerging trends, while IHI offers stable exposure to established medtech leaders.

Introduction

Investors seeking healthcare exposure often weigh thematic innovation against established sector plays. The FMED and IHI ETFs provide alternative pathways within this resilient sector. FMED targets disruptive medicine companies transforming diagnostics and therapies, appealing to growth-oriented portfolios. In contrast, IHI delivers precise access to U.S. medical device firms, benefiting from procedural volumes and aging demographics. These funds compete indirectly, with FMED offering broader, active innovation bets and IHI emphasizing passive, device-specific stability. Amid rising healthcare spending and technological advancements, comparing their structures reveals key trade-offs in risk, cost, and potential returns for diversified ETF portfolios.

Fidelity Disruptive Medicine ETF (FMED) Overview

The Fidelity Disruptive Medicine ETF (FMED) is an actively managed thematic fund seeking long-term capital growth by investing at least 80% of assets in securities of disruptive medicine companies. It focuses on innovations in robotic surgery, gene therapy, genomics, rare diseases, immunotherapy, and technology-based platforms. With 67-74 holdings, FMED employs fundamental analysis and quantitative tools to select domestic and foreign growth or value stocks.

Top holdings include DHR (Danaher Corp., ~3.8-4.1%), ISRG (Intuitive Surgical, ~3.5%), UCB SA (~3.4%), COGT (Cogent Biosciences, ~3.3%), and ALNY (Alnylam Pharmaceuticals, ~3.2%), with the top 10 representing 28-38% of assets.

Sector allocations are heavily weighted toward biotechnology (44%), health care equipment (17%), life sciences tools (12%), and pharmaceuticals (10%). The expense ratio is 0.50%, with a turnover rate of 26%. This structure suits investors pursuing high-conviction bets on medical breakthroughs.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passively managed fund tracking the Dow Jones U.S. Select Medical Equipment Index, which measures U.S. equities in medical devices such as MRI scanners, prosthetics, and pacemakers. It holds 47-52 securities, providing targeted exposure to manufacturers and distributors.

Top holdings are dominated by ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), SYK (Stryker, ~11%), EW (Edwards Lifesciences, ~5%), and IDXX (IDEXX Laboratories, ~4.7%), with the top 10 comprising over 75% of assets.

The portfolio is 100% healthcare-focused on medical equipment. The expense ratio stands at 0.38%, with low turnover around 16% and quarterly rebalancing to mirror the index. IHI's non-diversified structure and high liquidity make it ideal for sector rotation strategies.

Industry and Thematic Backdrop

The healthcare sector, particularly medtech and biotech, benefits from aging populations, rising chronic diseases, and innovation in AI-driven diagnostics and minimally invasive procedures. Capital flows into disruptive therapies like gene editing and immunotherapy have accelerated, fueled by regulatory approvals from the FDA (Food and Drug Administration). Macro drivers include steady U.S. healthcare spending growth, projected at 5-6% annually, and resilience amid economic cycles.

Challenges encompass reimbursement pressures, supply chain vulnerabilities, and regulatory scrutiny on device safety. Recent catalysts involve advancements in robotic surgery and precision medicine, boosting demand for both established devices and emerging biotech. Sector risks include policy shifts like drug pricing reforms and interest rate sensitivity for growth stocks.

Performance and Positioning Comparison

In recent market cycles, IHI has shown steadier positioning tied to procedural volumes and established leaders, exhibiting moderate volatility due to its concentrated large-cap focus. FMED, with biotech exposure, displays higher volatility linked to clinical trial outcomes and innovation momentum.

Relative performance varies with sector rotation: IHI gains in defensive healthcare phases, while FMED outperforms during biotech rallies driven by earnings from top holdings like ALNY or COGT. Both benefit from falling rates favoring growth, but IHI's U.S.-centric profile offers lower geopolitical risk compared to FMED's international elements. Over recent months, medtech stability has edged biotech amid economic uncertainty.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes like healthcare ETFs.

Tickeron AI Verdict

Tickeron’s AI currently favors IHI with moderate conviction (60-70% probability in the near term). Its lower expense ratio, established index methodology, superior liquidity, and concentrated exposure to proven U.S. medtech leaders provide structural advantages in stable sector environments. FMED's active approach and biotech tilt offer upside in innovation cycles but introduce higher volatility and costs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations